Cannabis Industry Lobbying Expenditures in 2026: Who’s Spending and on What

Cannabis industry lobbying has grown from a fringe advocacy effort into a sophisticated, multi-million-dollar influence operation spanning federal and state governments. In 2026, lobbying expenditures by cannabis companies, trade associations, and allied organizations are on pace to exceed $35 million at the federal level alone — a figure that does not capture the substantial spending occurring in state capitals across the country.

Understanding who is spending these dollars, what they are targeting, and how effectively lobbying translates into legislative outcomes provides essential context for anyone following cannabis policy developments.

Federal Lobbying Overview

Federal lobbying disclosures for the first quarter of 2026 show the cannabis industry continuing its steady spending escalation. The top spenders fall into three categories: multi-state operators (MSOs), trade associations, and ancillary companies seeking to normalize cannabis within existing regulatory frameworks.

Multi-State Operators: The largest MSOs collectively spend between $8 million and $12 million annually on federal lobbying. Curaleaf, Trulieve, Green Thumb Industries, and Cresco Labs each maintain dedicated lobbying teams or retain prominent K Street firms. Their primary legislative targets include banking reform (SAFE Banking Act and its successors), 280E tax reform, and interstate commerce provisions that would allow product transport between legal states.

Trade Associations: The National Cannabis Industry Association (NCIA), Cannabis Trade Federation, and U.S. Cannabis Council together spend approximately $5-7 million annually on federal lobbying and grassroots advocacy. These organizations represent broader industry interests and coordinate lobbying strategy across member companies. The NCIA’s annual Cannabis Industry Lobby Days event has grown into one of the largest industry advocacy gatherings, bringing hundreds of operators to Capitol Hill each spring.

Ancillary Companies: Financial services firms, technology companies, and real estate interests that serve the cannabis industry but do not touch the plant directly have emerged as significant lobbying voices. These companies — payment processors, software providers, insurance companies — lobby for regulatory clarity that would allow them to serve cannabis clients without federal legal risk.

Key Legislative Targets

Cannabis lobbying dollars in 2026 are concentrated around a handful of legislative priorities:

Banking Reform: The SAFE Banking Act has been reintroduced in various forms for seven consecutive congressional sessions. Each version has passed the House with bipartisan support, and each has stalled in the Senate. In 2026, the latest iteration includes provisions for Small Business Administration loan access and SEC reporting normalization alongside the core banking safe harbor. Industry lobbyists estimate that banking reform alone accounts for 40-50% of their federal lobbying effort and budget. The financial challenges facing cannabis businesses are documented in our coverage of cannabis banking and financial services.

280E Tax Reform: Section 280E of the Internal Revenue Code prohibits businesses trafficking in Schedule I or II controlled substances from deducting ordinary business expenses. This effectively taxes cannabis companies on gross revenue rather than net income, resulting in effective tax rates of 50-70% for some operators. Lobbying for 280E reform — either through rescheduling cannabis or through standalone tax legislation — is a top priority for MSOs facing margin pressure.

Rescheduling and Descheduling: The DEA’s ongoing review of cannabis scheduling, initiated by the Biden administration’s directive in 2022, continues to inch forward. Industry lobbying around scheduling focuses on both the administrative process at DEA and HHS and on congressional legislation that would bypass the administrative process entirely.

Interstate Commerce: As more states legalize, the prohibition on transporting cannabis across state lines creates significant inefficiency. Companies operating in multiple states must maintain separate cultivation, manufacturing, and distribution operations in each state. Lobbying for interstate commerce provisions would allow operators to consolidate production and distribute nationally, dramatically reducing costs.

State-Level Lobbying

While federal lobbying captures more attention, state-level lobbying by cannabis interests is equally significant — and often more immediately impactful.

In states with active legalization campaigns, industry groups spend heavily on ballot measure support, legislative testimony, and relationship-building with state legislators. In already-legal states, lobbying focuses on regulatory refinement: license caps, tax rates, social equity provisions, consumption lounge regulations, and home delivery rules.

State-level lobbying is harder to track because disclosure requirements vary widely. Some states require detailed lobbying expenditure reports; others have minimal transparency requirements. Industry observers estimate that combined state-level cannabis lobbying exceeds federal spending by a factor of two to three.

Notable 2026 state-level lobbying efforts include campaigns to expand licensing in New York, reform cultivation regulations in California, enable social consumption in multiple states, and prevent local opt-out provisions that limit dispensary availability. The expansion of new dispensary models is a topic we explore in our article on drive-through dispensary expansion.

The Lobbying Arms Race

Cannabis industry lobbying does not occur in a vacuum. Opposition spending from anti-cannabis organizations, pharmaceutical companies concerned about competition, and alcohol industry groups adds a competitive dimension to the lobbying landscape.

Smart Approaches to Marijuana (SAM), the most prominent anti-legalization organization, spends approximately $2-3 million annually on federal and state advocacy opposing cannabis normalization. While this is a fraction of industry spending, SAM’s messaging — focused on youth protection, impaired driving, and mental health — resonates with specific legislative audiences.

Pharmaceutical industry lobbying that intersects with cannabis policy is more difficult to quantify because it is rarely labeled as cannabis-specific. However, pharmaceutical trade groups have historically opposed policies that would facilitate cannabis as a competitor to FDA-approved medications, particularly in pain management and mental health applications.

The alcohol industry’s relationship with cannabis lobbying has shifted from opposition to cautious engagement. Several major alcohol companies have made strategic investments in cannabis, and alcohol trade groups have moderated their stance from outright opposition to advocacy for regulatory parity — essentially arguing that cannabis should face similar taxation and regulatory oversight as alcohol.

Effectiveness and Return on Investment

The central question for cannabis industry lobbyists is whether their spending is producing results. The record is mixed.

Successes: State-level legalization has expanded rapidly, and industry lobbying has played a role in shaping favorable regulatory frameworks in many states. At the federal level, the House has repeatedly passed cannabis banking legislation with bipartisan majorities — a direct reflection of industry lobbying efforts.

Frustrations: The Senate remains the graveyard for federal cannabis legislation. Despite years of lobbying and hundreds of millions in cumulative spending, no major standalone cannabis legislation has been signed into law at the federal level. The disconnect between lobbying investment and legislative outcomes at the federal level has prompted some industry leaders to question their Washington strategy.

Indirect benefits: Lobbying produces results beyond specific legislation. Relationships built through lobbying contribute to the normalization of cannabis within political circles, influence regulatory interpretation and enforcement priorities, and help prevent harmful legislation from advancing.

Emerging Trends in Cannabis Lobbying

Several trends are reshaping how the cannabis industry approaches political influence:

Coalition building: Cannabis lobbyists are increasingly partnering with criminal justice reform organizations, veterans groups, and medical advocacy organizations to broaden their legislative coalition beyond industry self-interest.

Political contributions: Cannabis industry PAC contributions and individual political donations have grown alongside lobbying spending. The Cannabis Trade Federation PAC and various company-affiliated PACs now contribute to candidates in both parties, reflecting the bipartisan nature of cannabis support among voters.

Grassroots mobilization: Industry groups are investing in grassroots advocacy tools that mobilize cannabis consumers and patients to contact their representatives. This complements traditional lobbying by demonstrating constituent demand for reform.

Local lobbying: Recognizing that local zoning and licensing decisions often determine market access, some companies are dedicating lobbying resources to municipal and county governments — a granular approach that was uncommon five years ago.

The Path Forward

Cannabis lobbying in 2026 reflects an industry that has professionalized its political engagement but continues to face structural obstacles at the federal level. The spending trajectory is upward, the strategies are increasingly sophisticated, and the political environment is more favorable than ever — yet the signature federal achievement that the industry has been lobbying for since Colorado legalized in 2012 remains elusive.

Whether the next congressional session finally delivers banking reform, tax relief, or broader federal action will determine whether the cannabis industry’s lobbying investment has been a long-term bet that pays off or a cautionary tale about the limits of influence in a polarized Congress.